How to Buy Stoke Therapeutics Stock
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies.
Stoke Therapeutics stock last closed at $31.00, up 2.45% from the previous day, and has increased 167.93% in one year. It has overperformed other stocks in the Biotechnology industry by 2.4 percentage points. Stoke Therapeutics stock is currently +177.53% from its 52-week low of $11.17, and -22.92% from its 52-week high of $40.22.
As of Jun 18, 2026, there are 62.28M shares of STOK outstanding. The market cap of STOK is $1.93B. In the past 24 hours, 1.97M STOK shares were traded.
How to Buy Stoke Therapeutics Stock
Wondering how to invest in Stoke Therapeutics stock? Here's how.
- Decide where to buy Stoke Therapeutics stock: You need to choose an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you decide where to buy Stoke Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your payment method and add your info.
- Evaluate Stoke Therapeutics stock: The Stoke Therapeutics ticker symbol is STOK. Is Stoke Therapeutics stock a good investment? Should you buy shares of STOK? How do STOK's underlying business fundamentals look? Do top analysts think Stoke Therapeutics is a good buy? Why has STOK's stock price moved recently? (Hint: Our stock research website can help you evaluate if STOK is a good stock to buy).
- Place your STOK purchase: Decide if you will purchase STOK shares at the current market price or use a limit order to purchase STOK shares at a given price.
- Track your STOK position: Create a watchlist to get the latest news on your new investment in Stoke Therapeutics stock.
Step 1: Decide where to buy Stoke Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy STOK shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal information so you can invest in STOK stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on the best stock trading app, you need to deposit funds:
Check out the video below for more details depositing funds into your new brokerage account.
Step 4: Evaluate Stoke Therapeutics stock
Once you have identified the best place to buy Stoke Therapeutics stock, it's critical to research their stock before you buy, so you actually understand the risk and upside.
Stoke Therapeutics quick stats
STOK Due Diligence Checks
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on STOK's stock page.
What is the fair value of STOK stock?
Analysts use many financial metrics, analyses, models, and charts to gauge STOK's true value.
Using relative valuations metrics:
- STOK could be undervalued based on its P/B ratio of 4.89x, relative to Biotechnology industry P/B ratio of 4.95x
You can access more valuation analysis on STOK's stock here.
STOK Financial Health Overview
Pros:
- There are more short-term assets than long-term liabilities on the STOK balance sheet.
- There are more short-term assets than short-term liabilities on the STOK balance sheet.
- STOK has a low debt to equity ratio of 0.12.
- STOK has cash burn of 147695000. It has sufficient cash and short-term investments to cover this for at least one year.
- STOK has $343.55M in cash and short term investments. This is sufficient to cover its annual cash burn of $147.70M.
Cons:
- STOK profit margin has gone down from 26.3% to -529.2% in the past year.
- Total STOK debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy STOK stock
Out of 6 Equities analysts who give forecasts on STOK, the consensus analyst rating on Stoke Therapeutics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest STOK Analyst Forecasts
Rudy Li, a top 3% analyst from Wolfe Research initiates coverage on STOK with a buy rating and announces their STOK price target of $40.00, on Feb 24, 2026.
You can dig deeper into what analysts are saying on the Stoke Therapeutics stock forecast page.
STOK Momentum
STOK Performance Numbers
Last year, STOK revenue was $32.08M. During the last four year, STOK's revenue has gone up by 80.83% per year. This was faster than the Biotechnology industry average of 32.37%.
Find out more about STOK's earnings and revenue performance here.
Are STOK insiders buying or selling the stock?
In the last 12 months, insiders at STOK have sold more shares than they have bought.
Jonathan Allan, GENERAL COUNSEL CORP SEC of STOK, was the latest STOK insider to sell. They sold $43,637.15 worth of STOK stock on Jun 16, 2026.
Learn more about who owns STOK shares here.
Does STOK provide a stable income stream?
No, Stoke Therapeutics doesn't provide an income stream by paying out dividends.
STOK Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your STOK purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally fine. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific dollar amount, place a limit order.
Click the Open button and your broker will execute the order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Track your STOK position
Now that you own some STOK shares, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to keep track of your STOK stock.
STOK Feed
How to Buy Stock in Stoke Therapeutics
To reiterate, here are the 6 steps you need to take to buy Stoke Therapeutics stock right now:
- Decide where to buy Stoke Therapeutics stock
- Create your brokerage account
- Deposit funds into your investment account
- Evaluate Stoke Therapeutics stock
- Place your STOK purchase
- Track your STOK position
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Stoke Therapeutics, add STOK to your watchlist by clicking the button below.
More Stock Buying Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.